- Active not recruitingPHASE3
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
This study, called POSEIDON, is testing new drug combinations for people with a type of lung cancer called non-small cell lung cancer (NSCLC). It's comparing usual chemotherapy with combinations of two new drugs, durvalumab and tremelimumab, to see if they work better.
For: Non Small Cell Lung Cancer NSCLCUnited States · Brazil · Bulgaria - Active not recruitingPHASE3
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
This study is for people with a type of lung cancer that can't be removed by surgery. It tests new drug combinations (Durvalumab with Oleclumab, or Durvalumab with Monalizumab) after standard treatment to see if they can help stop the cancer from coming back or getting worse.
For: Non-Small Cell Lung CancerUnited States · Australia · Brazil - RecruitingPHASE1, PHASE2
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
This study is testing new medicines, Gocatamig and Ifinatamab Deruxtecan (I-DXd), for advanced small cell lung cancer that has come back or isn't responding to treatment. Researchers want to see if these drugs, alone or together, are safe and can shrink the cancer.
For: Small Cell Lung CancerUnited States · Argentina · Australia - RecruitingPHASE2
PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer
This study looks at new treatments for triple negative breast cancer that hasn't fully responded to initial chemotherapy. We're testing if medicines, given briefly before surgery, can start to shrink the cancer or change it in helpful ways.
For: Breast Neoplasm · Triple Negative Breast Cancer (TNBC) · HRDUnited Kingdom - RecruitingPHASE2, PHASE3
Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features
This study looks at new treatments for endometrial cancer based on specific cancer features. It aims to find better ways to treat patients after surgery, potentially leading to personalised care for different types of endometrial cancer.
For: Endometrial CancerCanada · France · Netherlands - Active not recruitingPHASE3
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
This study looks at a new combination of drugs, ceralasertib and durvalumab, for people with advanced lung cancer that has grown after previous treatments. It compares this new combination to a standard chemotherapy drug, docetaxel, to see which works better and is safer.
For: Advanced or Metastatic Non-Small Cell Lung CancerUnited States · Argentina · Australia - Enrolling by invitationPHASE3
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab
This study is for cancer patients who have already been in another durvalumab drug trial and are still benefiting from the treatment. It lets them continue receiving the drug to see if it keeps helping them.
For: CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
This study is looking at two different treatments, pumitamig and durvalumab, for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that can't be removed by surgery. It's for patients who have already had chemotherapy and radiation.
For: Non-small Cell Lung Cancer (NSCLC)United States · Argentina · Australia - Active not recruitingPHASE1, PHASE2
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
This study is looking at new combinations of medicines for HER2-positive breast cancer that has spread. It aims to see how safe and effective these combinations are in patients whose advanced breast cancer has come back or spread.
For: Metastatic Breast CancerUnited States · Australia · Brazil - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
This study looks at new treatments for a type of lung cancer that hasn't spread widely but can't be removed by surgery. It aims to see how well these medicines work and if they are safe after standard initial treatments.
For: Non-Small Cell Lung CancerUnited States · Australia · Belgium - Active not recruitingPHASE3
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
This study looks at new drug combinations for bladder cancer that has spread into the muscle. It compares them to standard treatment for people who can't take or don't want cisplatin chemotherapy before surgery to remove their bladder. The aim is to find more effective and safe options.
For: Muscle Invasive Bladder CancerUnited States · Argentina · Austria - Active not recruitingPHASE3
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
This study looks at a new way to treat muscle-invasive bladder cancer using a drug called Durvalumab alongside standard chemotherapy. It aims to see if this combination, given before and after surgery, can improve treatment outcomes and safety for patients.
For: Muscle Invasive Bladder CancerUnited States · Australia · Belgium - Active not recruitingPHASE3
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
This study is testing new drug combinations for a type of kidney cancer called Papillary Renal Cell Carcinoma (PRCC). It compares a mix of savolitinib and durvalumab, or just durvalumab, against a standard treatment, sunitinib, for advanced PRCC linked to a specific genetic change.
For: Papillary Renal Cell CarcinomaUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr
This study, called DURANCE, is testing a new combination treatment for bladder cancer that hasn't spread into the muscle. It combines a vaccine (S-488210/S-488211) with an immunotherapy drug (durvalumab) to see if it's safe and effective in people who haven't responded well to previous treatments.
For: Bladder CancerUnited Kingdom - Active not recruitingPHASE2
A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition
This study looks at new treatments (Ceralasertib alone or with Durvalumab) for people with advanced melanoma that has stopped responding to standard immunotherapy. It aims to see how well they work and if they are safe.
For: MelanomaUnited States · Australia · Belgium - Active not recruitingPHASE3
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
This study is looking at new ways to treat a type of breast cancer that doesn't have certain hormone receptors or HER2 protein, called triple-negative or hormone receptor-low/HER2-negative breast cancer. It tests two different treatment plans using new and existing medicines before and after surgery.
For: Breast CancerUnited States · Australia · Austria - RecruitingPHASE3
Renal Adjuvant MultiPle Arm Randomised Trial
This study looks at new treatments for kidney cancer (renal cell carcinoma) after surgery. It compares two drugs, durvalumab and tremelimumab, given alone or together, against standard monitoring. The aim is to see if these drugs can stop the cancer from coming back or help people live longer.
For: Renal Cell CarcinomaUnited Kingdom - Active not recruitingPHASE1, PHASE2
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
This study looks at new drug combinations for advanced cancers. We want to see if they're safe, how well they work, and what effects they have on the body. It involves different stages to find the best doses and see benefits.
For: Advanced Solid TumorsUnited States · Australia · Belgium - RecruitingPHASE2
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
This study looks at new treatments for advanced stomach or oesophageal cancer with a specific protein called HER2. We're testing a new drug, trastuzumab deruxtecan, by itself or with other common cancer medicines to see if it's safe and effective.
For: Gastric CancerUnited States · Brazil · Canada - RecruitingPHASE2
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
This study is looking at a new treatment called JNJ-90301900 for a type of lung cancer. It combines this new drug with standard chemotherapy, radiation, and another immunotherapy to see if it helps more people get better.
For: Carcinoma, Non-Small-Cell LungUnited States · Australia · Brazil - Active not recruitingPHASE3
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
This study is looking at new ways to treat early-stage lung cancer that hasn't spread. It's testing if a drug called durvalumab, or another drug called osimertinib, when given after standard radiation therapy, can help improve outcomes for patients.
For: Carcinoma, Non-Small-Cell LungUnited States · Australia · Belgium - Active not recruitingPHASE2
Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer
This study is looking at whether a drug called durvalumab, given after surgery, chemo, and radiotherapy, can help people with bladder cancer. We want to see if it stops the cancer from growing or helps cancer cells die.
For: Bladder CancerCanada · Spain · United Kingdom - Active not recruitingPHASE3
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
This study looks at new treatments (Durvalumab, Tremelimumab) for a type of lung cancer, Small Cell Lung Cancer, after initial strong treatment. It aims to see if these drugs can stop the cancer from coming back.
For: Small Cell Lung CancerUnited States · Argentina · Belgium - Active not recruitingPHASE2
Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)
This study looks at new ways to treat advanced non-small cell lung cancer that hasn't spread after initial treatment. It compares two treatments: Durvalumab alone, and Durvalumab combined with Olaparib, to see if the combination helps patients live longer and better.
For: Non-small Cell Lung Cancer NSCLCUnited States · Belgium · Hungary - RecruitingPHASE3
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
This study is for adults with a certain type of lung cancer (Stage II-IIIB non-small cell lung cancer) that has a specific genetic change (HER2 mutation) and has been fully removed by surgery. It compares a new daily tablet called zongertinib with standard treatments to see if it can stop the cancer from coming back.
For: Non-small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE2
Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab
This study looks at a new way to quickly see if a cancer treatment called durvalumab is working for people with oesophageal cancer. We're testing if changes in a blood marker (ctDNA) can tell us sooner than scans if the treatment is helping.
For: Oesophageal CancerUnited Kingdom - Active not recruitingPHASE3
CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)
The CompARE trial is testing new treatments for a type of throat cancer called oropharyngeal cancer. It compares different ways of using radiotherapy, surgery, and immunotherapy to see if they improve survival and quality of life for adults with more advanced forms of this cancer.
For: Oropharyngeal CancerIreland · United Kingdom - RecruitingPHASE3
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
This study is looking at new ways to treat advanced bile duct cancer. It compares two drug combinations: rilvegostomig with chemotherapy, and durvalumab with chemotherapy, to see which is safer and works better as a first treatment.
For: Biliary Tract CancerUnited States · Australia · Belgium - Active not recruitingPHASE3
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
This study looks at new ways to treat advanced lung cancer that can't be removed by surgery. It combines standard chemotherapy and radiation with newer drugs, pembrolizumab and olaparib, to see if they can improve survival compared to current treatments.
For: Lung Neoplasms · Carcinoma, Non-Small-Cell LungUnited States · Argentina · Canada - RecruitingPHASE1
A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC
This study looks at combining radiotherapy with new drugs to treat non-small cell lung cancer that hasn't spread widely. Researchers want to find the safest and most effective dose of these new drugs, which help radiotherapy work better by making it harder for cancer cells to repair themselves.
For: Non Small Cell Lung CancerUnited Kingdom - Active not recruitingPHASE3
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)
This study is looking at a new treatment called Durvalumab for advanced bile duct and gallbladder cancer. It's given alongside standard chemotherapy to see if it helps patients live longer and better. It's for people whose cancer is advanced and hasn't been treated yet, or has come back after a long time.
For: Biliary Tract NeoplasmsUnited States · Argentina · Bulgaria - Active not recruitingPHASE3
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
This study is testing a new combination of treatments for adults with advanced lung cancer (NSCLC) that hasn't spread to the brain or spine and doesn't have certain genetic changes. It compares this new treatment to a standard one, hoping it works better.
For: NSCLCUnited States · Austria · Brazil - RecruitingPHASE3
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
This study is testing a new drug, olomorasib, for a specific type of lung cancer (NSCLC) with a KRAS G12C gene change. It checks if olomorasib, combined with standard treatments, works better than standard treatments alone for people with either resected or unresectable cancer.
For: Carcinoma, Non-Small-Cell LungUnited States · Australia · Austria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
MOIO_Randomized phase III trial of standard immunotherapy (IO) by checkpoint inhibitors, versus reduced dose intensity of IO in patients with locally advanced or metastatic cancer in response after 6 months of standard IO
This study compares standard immunotherapy with a reduced dose for people whose cancer responded well after 6 months. It looks at how long they stay well and their quality of life. The aim is to see if a lower dose can be just as effective.
For: Only patients with oncologic locally advanced or metastatic tumour (lung cancer · renal cell cancer (except IMDC favorable-risk treated Tyrosine Kinase Inhibitor [TKI] / immunotherapy [IO] combination) · head and neck cancerFrance - AuthorisedTherapeutic exploratory (Phase II)
AUSTRAL trial: An open-label, multicenter, phase II study of radiotherapy followed by durvalumab (MEDI4736) and ceralasertib (AZD6738) in stage III NSCLC patients with thoracic relapses +/- oligometastases after PACIFIC regimen
This study looks at a new treatment for stage III lung cancer that has returned. It combines radiation therapy with two drugs, durvalumab and ceralasertib, to see how safe and effective this combination is for patients.
For: regardless of PD-L1 status · but without EGFR · HER-2 or MET exon14 skipping mutationsItaly - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Nonsmall Cell Lung Cancer (LA NSCLC)
This study is looking at new ways to treat a type of lung cancer that hasn't spread widely. It compares standard treatments with new drug combinations to see if they can stop the cancer from growing for longer. It aims to find the best treatment for patients with this type of lung cancer.
For: Previously Untreated Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)France · Netherlands · Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2a, double-blind, placebo-controlled, multi-center, randomized study evaluating LSTA1 when added to standard of care (SoC) versus standard of care alone in subjects with advanced solid tumors (BOLSTER)
This study is looking at a new treatment called LSTA1 for people with advanced head and neck cancer or a type of bile duct cancer (cholangiocarcinoma). It aims to see if adding LSTA1 to standard treatments is safe and helps people live longer and feel better.
For: Head and neck cancer · CholangiocarcinomaSpain - Ongoing, recruitingPhase III and phase IV (Integrated)
Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab with Pembrolizumab) in Combination with Concurrent Chemoradiotherapy followed by MK7684A Versus Concurrent Chemoradiotherapy followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III NSCLC (KEYVIBE-006)
This study is looking at new ways to treat advanced lung cancer that can't be removed by surgery. It compares a new combination of medicines with a standard treatment, both given with chemotherapy and radiotherapy, to see which works best.
For: Non-small cell lung cancerSpain · Italy · Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
Precision Immuno-Oncology for advanced Non-small cell lung cancer patients with PD-1 ICI Resistance (PIONeeR clinical study)
This study is for adults with a type of advanced lung cancer (non-small cell lung cancer) that has stopped responding to previous immune-boosting treatments. It's testing new combinations of medicines to see if they can help control the cancer, looking at how many people's cancer stops growing or shrinks after 12 weeks.
For: non small cell lung cancerFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, open label, single arm, multicentre study on THOracic Radiotherapy in Extensive Stage SCLC patients submitted to first line CHT-RT plus Durvalumab (MEDI4736)
This study is looking at a new way to treat extensive small cell lung cancer. It combines standard chemotherapy with radiotherapy and a drug called Durvalumab. Researchers want to see if this combination can help people live longer without their cancer getting worse.
For: Extended stage small cell lung cancer patients confirmed histologically in full · partial or stable response after platinum-etoposide chemo-immunotherapy candidate to maintenance immunotherapy with Durvalumab.Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Cancer (BR31)
This study is looking at a new drug called durvalumab (also known as MEDI4736) for people who have had surgery for a certain type of lung cancer. It aims to see if the drug can stop the cancer from coming back, especially in those with specific cancer markers.
For: Completely resected primary stage IB (≥ 4cm) · II and IIIA non-small cell lung cancer patientsBulgaria · Spain · Romania - AuthorisedTherapeutic exploratory (Phase II)
Phase II study of Durvalumab (MEDI4736) plus Total Neoadjuvant Therapy (TNT) in locally advanced rectal cancer (The DUREC trial)
This study is looking at a new way to treat locally advanced rectal cancer. It combines standard chemotherapy and radiotherapy with a new drug called Durvalumab to see if this combination causes the cancer to completely disappear before surgery.
For: Locally advanced rectal cancerSpain - AuthorisedTherapeutic exploratory (Phase II)
Perioperative Therapy with Durvalumab Plus Tremelimumab for Patients with Resectable Hepatocellular Carcinoma (HCC) - A Phase II Trial (NEOTOMA)
This study is testing two medicines, durvalumab and tremelimumab, before surgery for liver cancer. We want to see if these medicines cause side effects that stop surgery or are hard to manage. It's a Phase II trial, meaning we're looking at safety and early signs of how well it works.
For: Resectable Hepatocellular CarcinomaSpain · Italy - RecruitingPHASE1
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
This study is testing a new drug, Ris-Rez, for people with advanced cancers. Researchers want to see if it's safe, how it works, and if it can help stop cancer growth, both alone and with other medicines.
For: NeoplasmsUnited States · Argentina · Canada - Active not recruitingPHASE2
ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss
This study looks at new treatments for gynaecological cancers that have come back. It tests a drug called ceralasertib, sometimes with olaparib or durvalumab, to see how well they work in different types of cancer cells, especially those with a specific gene change called ARID1A loss.
For: Gynaecological CancersCanada · United Kingdom - RecruitingPHASE3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
This study looks at new treatments for a type of breast cancer called triple-negative. It compares a new drug, Dato-DXd, sometimes with Durvalumab, against standard chemotherapy with Pembrolizumab for patients whose cancer has come back locally or spread.
For: Breast CancerUnited States · Argentina · Australia - AuthorisedTherapeutic use (Phase IV)
ETCABio - Evaluation of Skin Tests in Biotherapy Allergies
This study looks at how your skin reacts to certain advanced cancer medicines, called biotherapies. We're finding the strongest dose that doesn't cause a skin reaction in most people when tested on the skin, to make these treatments safer.
For: deficient mismatch repair (dMMR) colorectal cancer · Follicular lymphoma · Chronic lymphocytic leukemia (CLL)France - RecruitingPHASE3
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
This study is testing a new drug called Zanidatamab for people with advanced HER2-positive biliary tract cancer. It compares this new drug combined with standard treatments to standard treatments alone, to see if it's more effective and safe.
For: Biliary Tract CancerUnited States · Argentina · Belgium - Active not recruitingPHASE1, PHASE2
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
This study looks at new drug combinations for metastatic triple-negative breast cancer. It combines standard treatment with new medicines (like Durvalumab) to see if they're safe and work well together for patients whose cancer has spread.
For: Triple Negative Breast NeoplasmsUnited States · Canada · Poland - Active not recruitingPHASE3
Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer
This study looks at a new drug, durvalumab, and standard chemotherapy (FLOT) for stomach or food pipe cancer that can be removed by surgery. It aims to see if this combination, given before and after the operation, is safe and effective.
For: Gastrointestinal Neoplasms · Esophagogastric JunctionUnited States · Argentina · Belgium